Document is current
Any future updates will be listed below
-
Authors
Le Couteur, David G. https://orcid.org/0000-0002-4227-5817
Ngu, Meng C. https://orcid.org/0009-0007-1018-5618
Hunt, Nicholas J. https://orcid.org/0000-0002-9001-0602
Brandon, Amanda E.
Simpson, Stephen J. https://orcid.org/0000-0003-0256-7687
Cogger, Victoria C. https://orcid.org/0000-0002-6346-9928
- License Information
-
More Information
Article History
Accepted: 26 June 2025
First Online: 28 July 2025
Competing interests
: D.G.L.C. has received consultancy fees via the Reimbursement Advisory Expert Panel (REAP) for independent pre-submission advice to pharmaceutical companies on regulatory and funding applications to government. D.G.L.C., N.J.H. and V.C.C. are founder members and N.J.H. is the CEO of a start-up company (Endo Axiom) with Sydney University, Sydney Local Health District and Proto Axiom, which hold patents on nanomedicines for the treatment and prevention of diabetes mellitus. The other authors declare no competing interests.
